Effects of intra-articular sodium pentosan polysulfate and glucosamine on the cytology, total protein concentration and viscosity of synovial fluid in horses

Australian Veterinary Journal

Volumn 90, Issue 8, 2012, Pages 315-320

  Kwan, C ^a   Bell, R ^a   Koenig, T ^a   Bischofberger, A ^a   Horadagoda, N ^a   Perkins, Nr ^b   Jeffcott, Lb ^a   Dart, Aj ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUSVET ANIMAL HEALTH SERVICES   (Australia)

Author keywords

Glucosamine; Horses; Intra articular administration; Pentosan polysulfate; Synovial fluid

Indexed keywords

ANTICOAGULANT AGENT; GLUCOSAMINE; PENTOSAN POLYSULFATE; PLASMA PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECT; FORELIMB; HORSE; HORSE DISEASE; INTRAARTICULAR DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYNOVIAL FLUID; SYNOVITIS; VISCOSITY;

ANIMALS; ANTICOAGULANTS; BLOOD PROTEINS; CARPUS, ANIMAL; GLUCOSAMINE; HORSE DISEASES; HORSES; INJECTIONS, INTRA-ARTICULAR; PENTOSAN SULFURIC POLYESTER; SYNOVIAL FLUID; SYNOVITIS; VISCOSITY;

EQUIDAE;

EID: 84864316254     PISSN: 00050423     EISSN: 17510813     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2012.00959.x     Document Type: Article

References (41)

1. Dart AJ, Perkins N, Dowling BA etal. The effect of three different doses of sodium pentosan polysulphate on haematological and haemostatic variables in adult horses. Aust Vet J 2001;79:624-627.
2. Fuller CJ, Ghosh P, Barr ARS. Plasma and synovial concentrations of calcium pentosan polysulphate achieved in the horse following intramuscular injection. Equine Vet J 2002;34:61-64.
3. Goodrich LR, Nixon, AJ. Medical treatment of osteoarthritis in the horse: a review. Vet J 2006;171:51-69.
4. Pearson W, Lindinger M. Critical review of research evaluating glucosamine-based nutraceuticals for treatment of joint pain and degenerative joint disease in horses. Proc Eur Equine Health Nutr Congr 2008;4:81-91.
5. Trumble TN. The use of nutraceuticals for osteoarthritis in horses. Vet Clin North Am Equine Pract 2005;21:575-597.
6. McCarty MF, Russell AL, Seed MP. Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial fluid hyaluronic acid synthesis. Med Hypoth 2000;54:798-802.
7. Smith MM, Ghosh P, Numata Y, Bansal MK. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex. Arthritis Rheum 1994;37:125-136.
8. Little C, Ghosh P. Potential use of pentosan polysulfate for the treatment of equine joint disease. In: McIlwraith C, Trotter G, editors. Joint disease in the horse. Saunders, Philadelphia, 1996;281-292.
9. Francis DJ, Forrest MJ, Brooks PM, Ghosh P. Retardation of articular cartilage degradation by glycosaminoglycan polysulfate, pentosan polysulfate, and DH-40J in the rat air pouch model. Arthritis Rheum 1989;32:608-616.
10. Dechant JE, Baxter GM. Glucosamine and chondroitin sulphate as structure modifying agents in horses. Equine Vet Educ 2007;19:90-96.
11. Neil KM, Caron JP, Orth MW. The role of glucosamine and chondroitin sulphate in treatment for and prevention of osteoarthritis in animals. J Am Vet Med Assoc 2005;226:1079-1088.
12. Block JA, Oegema TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthr Cart 2010;18:5-11.
13. Millar KL, Clegg DO. Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am 2011;37:103-118.
14. Vista ES, Lau CS. What about supplements for osteoarthritis? A critical and evidence based review. Rheum Dis Clin North Am 2011;14:152-158.
15. Pearson W, Lindinger M. Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: review of in vivo studies. Equine Vet J 2009; 49:706-712.
16. Frisbie DD, Kawcak CE, McIlwraith CW, Werpy NM. Assessment of intravenous or intra-articular hyaluronic acid, chondroitin sulfate, and N-acetyl-D-glucosamine in treatment of osteoarthritis using an equine experimental model. Proc Ann Conv Am Assoc Equine Pract 2008;54:250-251.
17. Scotto d'Abusco A, Corsi A, Grazia Grillo M etal. Effects of intra-articular administration of glucosamine and a peptidyl-glucosamine derivative in a rabbit model of experimental osteoarthritis: a pilot study. Rheum Int 2008;28:437-443.
18. Vajaradul Y. Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther 1981;3:336-343.
19. Ekmann A, Rigdal M, Gröndahl G. Automated counting of nucleated cells in equine synovial fluid without and with hyaluronidase pretreatment. Vet Clin Pathol 2010;39:83-89.
20. Hasselbacher P. Measuring synovial fluid viscosity with a white blood cell diluting pipette. Arthritis Rheum 1976;19:1358-1362.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.
22. Steel CM. Equine synovial fluid analysis. Vet Clin North Am Equine Pract 2008;24:437-454.
23. Persson L. On the synovial fluid in horses. Acta Vet Scand Suppl 1971;35:1-77.
24. Van Pelt RW. Interpretation of the synovial fluid findings in the horse. J Am Vet Med Assoc 1974;165:91-95.
25. Francoz D, Derochers A, Latouche JS. Effect of repeated arthrocentesis and single joint lavage on cytologic evaluation of synovial fluid in 5 young calves. Can J Vet Res 2007;71:129-134.
26. Wagner AE, McIlwraith CW, Martin GS. Effect of intra-articular injection of orgotein and saline solution on equine synovial. Am J Vet Res 1982;43:594-597.
27. Stover SM, Pool RR. Effect of intra-articular gentamicin sulphate on normal equine synovial membrane. Am J Vet Res 1985;46:2485-2491.
28. White KK, Hodgson DR, Hancock D etal. Changes in equine carpal joint synovial fluid in response to injection of two anaesthetic agents. Cornell Vet 1989;79:25-28.
29. Lloyd KC, Stover SM, Pascoe JR etal. Effect of gentamicin sulphate and sodium bicarbonate on the synovium of clinically normal equine antebrachiocarpal joints. Am J Vet Res 1988;49:650-657.
30. Mills ML, Rush BR, St Jean G etal. Determination of synovial fluid concentrations and morphologic effects of intra-articular ceftiofur sodium in horses. Vet Surg 2000;29:398-406.
31. Taintor J, Schumacher J, Degraves F. Comparison of amikacin concentrations in normal and inflamed joints of horses following intra-articular administration. Equine Vet J 2006;38:189-191.
32. Dykgraaf S, Dechant JE, Johns JL etal. Effect of intrathecal amikacin administration and repeated centesis on digital flexor tendon sheath synovial fluid in horses. Vet Surg 2007;26:57-63.
33. Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate in man (SP54) and heparin. I: mechanism of action on blood coagulation. Thromb Haemost 1982;47:104-108.
34. Ohme CE, Harris RC. A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse. Acta Physiol Scand 1997;159:179-185.
35. Soria C, Soria J, Ryckewaert JJ etal. Anticoagulant activities of pentosan polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980;19:455-463.
36. Fischer AM, Merton RE, Marsh NA etal. A comparison of pentosan polysulphate and heparin. II: effects of subcutaneous injection. Thromb Haemost 1982;47:109-113.
37. Czapek EE, Kwaan HC, Szczecinski M. The effect of a sulphated polysaccharide on antithrombin III. J Lab Clin Med 1980;95:783-790.
38. Vinnazer H, Haas S, Sternberger A. influence on the clotting mechanism of sodium pentosan-polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980;20:57-59.
39. Dunn F, Soria J, Soria C etal. Fibrinogen binding on human platelets: influence of different heparins and of pentosan polysulphate. Thromb Res 1983;29:141-148.
40. De Prost D, Guerot C, Karsenty F. Pentosan polysulphate: the effect on haemostasis of a continuous 3-day infusion. Clin Pharmacol Ther 1985;38:171-175.
41. Dougados M, Hawker G, Lohmander S etal. OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs. J Rheumatol 2009; 36:2097-2099.